Leadership

About V-WAVE

Senior Management Team

Neal Eigler, MD | CEO

Dr. Neal Eigler joined V-Wave as its CEO in early 2015 and has since overseen the development of the company’s senior management team, the evolution of its shunt products and successfully concluded B and C round private equity financings. 

Dr. Eigler’s career spans 45 years in medicine and more 30 years as a MedTech inventor and entrepreneur. He is board certified in Internal Medicine, Cardiovascular Diseases, and Interventional Cardiology. In 1985, he joined the fulltime staff of the Division of Cardiology at Cedars-Sinai Medical Center and achieved the academic rank of Professor of Medicine at UCLA. He served as Co-Director, then Director of the Cardiac Intervention Center at Cedars-Sinai for two decades.

Prior to joining V-Wave, he co-founded and was Medical Director of Progressive Angioplasty Systems and later Conor Medsystems (CONR), who developed a multi-drug delivery stent platform with programmable elution kinetics. The company went public in 2004 and was acquired by Johnson & Johnson in 2006.  The technology was sold to Micropart in 2014, where it became the basis for the Firehawk Liberty™ coronary stent system. In 2000, Dr. Eigler founded and served as CEO for Savacor, Inc., where he invented a system for managing heart failure with an implantable left atrial pressure sensor using a clinician-directed patient self-management data interface. Savacor was acquired by St. Jude (Abbott Laboratories) in 2006, where Dr. Eigler stayed on as a Senior Vice President of Technology Incubation through 2014. He is listed as an inventor on over 50 US patents.

Dr. Eigler did his undergraduate studies in Cybernetic Engineering at UCLA  before attending Yale University School of Medicine. His medical residency and cardiology fellowship training were at Cedars-Sinai Medical Center in Los Angeles.

Erez Rozenfeld | President

Erez Rozenfeld joined V-Wave in 2013.  He has more than three decades of proven track record in successful initiation and execution of high-return global business development in the field of medical devices.  He has implemented new business models and strategic plans, overseen mergers and acquisitions, and helped medical innovation companies engage new markets, globally.

Rozenfeld served as CEO of V-Wave prior to global expansion.  His prior industry experience includes being Managing Director at Lumenis UK, as well as in key managerial positions for publicly traded companies, including Teva Group and Agis.  He has expertise in managing emerging companies as Senior VP global operations at Aesthera Inc., CEO of RapiX.

Rozenfeld holds an Executive MBA and BA from Bar Ilan University, Israel.

William T. Abraham, MD | CMO

Dr. William Abraham has been affiliated with V-Wave since 2013, initially as Chairman of its Strategic Advisory Board, then as its Chief Medical Officer in 2015, and becoming the full-time CMO in 2019.  He is responsible for coordinating the activities of the Department of Medical Affairs and serves as a key member of the Senior Management team.

Dr. Abraham is Professor of Internal Medicine, Physiology and Cell Biology and a College of Medicine Distinguished Professor at The Ohio State University, where he formerly served as Director of Cardiovascular Medicine for more than 15 years.  He is an internationally renowned clinician, academician, and researcher in heart failure and has been recognized as one of the “Best Doctors in America” for 18 consecutive years.  His research interests include hemodynamic and neurohormonal mechanisms and clinical drug and device trials in heart failure.  He has led studies that established several new therapies as standard of care for heart failure.  Dr. Abraham has participated as a site principal investigator in over 100 multi-center drug and device clinical trials; additionally, he served as national or international principal investigator or on the executive and steering committees of more than 40 multi-center drug and device trials.  He has authored more than 400 full-length peer-reviewed publications.  Dr. Abraham has consulted for dozens of medical device and pharmaceutical companies and has extensive regulatory experience in the cardiorenal drug and cardiocirculatory system devices arenas in the United States and Europe.

Dr. Abraham received his undergraduate degree from the University of Pittsburgh and then attended Harvard Medical School.  He was Resident and Chief Resident and then a Fellow in Cardiology and Advanced Heart Failure/Transplant Cardiology at the University of Colorado Health Sciences Center.

William Hughes | CFO

William Hughes was appointed as V-Wave Chief Financial Officer in late 2020.  Mr. Hughes brings more than 20 years of financial and operational experience in senior executive leadership positions in the medical device industry.  His accomplishments include successfully managing privately and publicly held enterprises and offering expertise in scaling companies globally, managing operations and finance, and successfully completing fundraising and M&A transactions. 

Hughes served as COO and CFO for southern California-based Microvention since 2002, successfully guiding that company through M&A with Terumo Corporation.  Before that he held executive positions at Endocare, Inc., Filenet Corporation as was a Partner at KPMG Peat Marwick. 

He has an undergraduate degree in Economics from California Polytechnic State University.

Matt Borenzweig | Executive Vice President

Matt Borenzweig joined V-Wave in June 2019, bringing with him three decades of experience in sales, marketing and clinical trial execution in the cardiovascular arena. He has held leadership positions at Boston Scientific, Arterial Vascular Engineering (AVE), Medtronic, CardioMEMS, Edwards Lifesciences and Abbott.  At Abbott, he held the position of Division VP of Structural Heart where he managed all commercial aspects of the Abbott’s product portfolio in the United States.

Borenzweig has been involved with many groundbreaking product launches including aortic and mitral valvuloplasty, temperature sensing RF ablation, novel coronary and peripheral stents, AAA stent grafts, implantable sensors for remote heart failure pressure monitoring, novel heart valves and valve repair, next generation MitraClip TMVr, PFO, PDA, and septal occluders.

He has an undergraduate degree in Biological Sciences from the University of Southern California.

Lior Rosen | Vice President, R&D

Lior Rosen joined V-Wave in 2014 and has been instrumental in developing and scaling up its technology, clinical programs, and operations. He brings more than 20 years of executive managerial experience in medical device development from concept through commercialization with focus on cardiovascular products. Prior to joining V-Wave, Rosen served as VP R&D and Co-CEO at CorAssist Cardiovascular.  Rosen holds a B.Sc. in Mechanical Engineering from the Technion and M.Sc. in Biomedical Engineering from Tel Aviv University.

Dudy Stolick | Vice President, Finance

Dudy Stolick’s 30-year career covers multiple finance leadership positions in life science and electronics industries.  He has previously held CFO roles at Exalenz Bioscience Ltd., and Brainstorm Cell Therapeutics, and has served a corporate controller for M-Systems.  Stolick holds a BA degree in Economy and Accounting from Ben Gurion University.

Lydia Telep | Vice President, Regulatory Affairs

Lydia Telep has a distinguished career in the medical device regulatory field spanning over 30 years.  Before joining V-Wave, she was the VP of Regulatory Affairs for Second Sight Medical Products and a Director of Regulatory Affairs at Abbott / St. Jude Medical.  Telep holds a MS in Bioengineering from California State University, Northridge (CSUN) and did her undergraduate studies at UCLA.

Gali Tzury | Vice President, Quality Assurance

Gali Tzury has over twenty years of medical technology experience across quality and regulatory matters.  Previously she has served as Vice President, QA/RA/CA at Rapid Medical and as a QA Manager at Alma Lasers.  She holds a BA from Bar Ilan University and a CQE from Technion Institute of Technology.

Werner Hafelfinger | Vice President, Operations

Werner Hafelfinger has a career that spans four decades across both the medtech and aerospace industries.  Before joining V-Wave he served as VP of Operations, Manufacturing, and R&D at St. Jude Medical.  Prior to that role, he was VP of Operations at Savacor, Inc.  Hafelfinger had originally started his career in the aerospace industry, including a leadership position as COO / Vice President of Operations at Pacific Aerospace & Electronics.  He holds a MS degree from Columbia University in Mechanical Engineering.

Board of Directors

Frank Litvack, MD | Chairman

Dr. Frank Litvack received his MD from McGill University and was trained in Cardiology at Cedars-Sinai Hospital. From 1986-2000 he was Co-Director of the Cardiovascular Intervention Center. He was Professor of Medicine at UCLA School of Medicine. Dr. Litvack has co-founded, operated and served as Chairman of a number of innovative companies including:

  • Chairman of Progressive Angioplasty System (PAS), the developer of the stent delivery system for the original Palmaz-Schatz stent and other products. PAS was acquired by U.S. Surgical in 1997.
  • CEO and Chairman of Conor MedSystems, a developer of innovative drug eluting stent technology. Dr Litvack took Conor public in 2004 and it was later acquired by Johnson & Johnson in 2007.
  • Chairman of Savacor, a left atrial pressure monitoring company that was acquired by St. Jude Medical in 2005.

Dr. Litvack currently serves on several corporate Boards and is a Founding Partner of Pura Vida Funds LLC, a healthcare investment firm.

Neal Eigler, MD | CEO

Dr. Neal Eigler joined V-Wave as its CEO in early 2015 and has since overseen the development of the company’s senior management team, the evolution of its shunt products and successfully concluded B and C round private equity financings. 

Dr. Eigler’s career spans 45 years in medicine and more 30 years as a MedTech inventor and entrepreneur. He is board certified in Internal Medicine, Cardiovascular Diseases, and Interventional Cardiology. In 1985, he joined the fulltime staff of the Division of Cardiology at Cedars-Sinai Medical Center and achieved the academic rank of Professor of Medicine at UCLA. He served as Co-Director, then Director of the Cardiac Intervention Center at Cedars-Sinai for two decades.

Prior to joining V-Wave, he co-founded and was Medical Director of Progressive Angioplasty Systems and later Conor Medsystems (CONR), who developed a multi-drug delivery stent platform with programmable elution kinetics. The company went public in 2004 and was acquired by Johnson & Johnson in 2006.  The technology was sold to Micropart in 2014, where it became the basis for the Firehawk Liberty™ coronary stent system. In 2000, Dr. Eigler founded and served as CEO for Savacor, Inc., where he invented a system for managing heart failure with an implantable left atrial pressure sensor using a clinician-directed patient self-management data interface. Savacor was acquired by St. Jude (Abbott Laboratories) in 2006, where Dr. Eigler stayed on as a Senior Vice President of Technology Incubation through 2014. He is listed as an inventor on over 50 US patents.

Dr. Eigler did his undergraduate studies in Cybernetic Engineering at UCLA  before attending Yale University School of Medicine. His medical residency and cardiology fellowship training were at Cedars-Sinai Medical Center in Los Angeles.

Alon Maor | BRM Group

Alan Maor, Partner at BRM, is responsible for life science investments in the firm. He has an extensive background in healthcare as a senior executive with over 22 years experience in the medical device business.

Maor is currently the Chairman of StrarletDerma and Perfaction.

Andrew ElBardissi | Deerfield Management

Dr. Andrew ElBardissi is a Principal at Deerfield Management focusing on early to late venture investments in medical technology. Prior to joining Deerfield, he was a Principal at Longitude Capital and served as an Associate in JP Morgan’s Healthcare Investment Banking practice.

Dr. ElBardissi completed his residency training in General Surgery at Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He received an MD from the Mayo Clinic, an MPH from Harvard University, and an MBA from Harvard Business School.

Jacques Essinger | Endeavour Vision

Dr. Jacques Essinger, Operating Partner at Endeavour since 2017, has more than 30 years of entrepreneurial experience in medical devices ranging from product design, clinical and regulatory validation, scale-up and commercial growth, financing, IPO and trade-sale.

Dr. Essinger was CEO of Symetis SA (acquired by Boston Scientific in March 2017), which he grew from concept to an established global market player in the field of Transcatheter Aortic Valve Implant (TAVI). Previously, he was CEO of Isotis (IPO in 2000, acquired by Integra Lifescience in 2007) and founded Symbios Orthopedie SA.  Essinger has a MSc in physics and a PhD in biomechanics from the EPFL (Lausanne).

Karimah Es Sabar | Quark Venture

Karimah Es Sabar is CEO & Partner at Quark Venture Inc, which has established one of the largest global health sciences venture funds in partnership with GF Securities, a leading investment bank in China.  Es Sabar is a highly recognized Canadian life sciences leader and she has served as President & CEO for The Centre for Drug Research and Development, Canada’s national drug development and commercialization center; Head of Marketing and Business Development at Pasteur Merieux Connaught [Sanofi Pasteur], and COO for Medsurge Medical Inc.

Es Sabar holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management, a MSc degree in Neurochemistry from the University of London, and a BSc Biochemistry/Chemistry from the University of Salford.

Tomer Kariv | Pontifax

Tomer Kariv is Co-founder and Chief Executive Officer of Pontifax, a group of Israeli-based life sciences venture funds focusing on investments in bio-pharmaceutical and med-tech technologies.

Kariv has also served as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning.

Kariv practiced law with Sullivan & Cromwell, a leading corporate law firm in New York, and holds a B.A. degree in Economics from Harvard University and a J.D. from Harvard Law School.